- Home
- CD vs EYPT Comparison
CD vs EYPT Comparison
Compare CD & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CD | EYPT |
|---|---|---|
| Founded | 2011 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.4M | 273.3M |
| IPO Year | 2014 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CD | EYPT |
|---|---|---|
| Price | $5.28 | $0.36 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $8.44 |
| AVG Volume (30 Days) | 379.7K | ★ 16.2M |
| Earning Date | 08-31-2023 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,867,068.00 | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $126.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 277.93 | N/A |
| 52 Week Low | $2.10 | $0.34 |
| 52 Week High | $14.10 | $19.11 |
Technical Indicators
Market Signals| Indicator | CD | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 16.83 |
| Support Level | $4.86 | N/A |
| Resistance Level | $6.10 | $3.57 |
| Average True Range (ATR) | 1.59 | 0.04 |
| MACD | -0.47 | 0.10 |
| Stochastic Oscillator | 5.56 | 14.18 |
Price Performance
Historical ComparisonAbout CD Chaince Digital Holdings Inc. Ordinary Shares
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.